CHDR Annual Report 2023
Scientific output

Our publications in 2023

  • Jennings D, Huntwork-Rodriguez S, Vissers MFJM, et al. LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease. Mov Disord. 2023; 38(3):386-398.
  • Te Beek ET, Burggraaf J, Teunissen JJM, Vriens D. Clinical Pharmacology of Radiotheranostics in Oncology. Clin Pharmacol Ther. 2023; 113(2):260-274.
  • Bai H, Bosch JJ, Heindl LM. Current management of uveal melanoma: A review. Clin Exp Ophthalmol. 2023; 51(5):484-494.
  • de Jong LM, Boussallami S, Sánchez-López E, et al. The impact of CYP2C19 genotype on phenoconversion by concomitant medication. Front Pharmacol. 2023; 14:1201906.
  • Clahsen T, Hadrian K, Notara M, et al. The novel role of lymphatic vessels in the pathogenesis of ocular diseases. Prog Retin Eye Res. 2023; 96:101157.
  • den Heijer JM, Cullen VC, Pereira DR, et al. A Biomarker Study in Patients with GBA1-Parkinson's Disease and Healthy Controls. Mov Disord. 2023; 38(5):783-795.
  • den Heijer JM, Kruithof AC, Moerland M, et al. A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator. Mov Disord. 2023; 38(7):1197-1208.
  • Goncalves LN, van Velze V, Klok FA, et al. High on-treatment platelet reactivity in peripheral arterial disease: A systematic review. Vascular. Published online 2023.
  • Stuijt DG, Radanovic I, Kos M, et al. Smartphone-Based Passive Sensing in Monitoring Patients With Cancer: A Systematic Review. JCO Clin Cancer Inform. 2023; 7:e2300141.
  • Bolognani F, Kruithof AC, Schulthess P, et al. Characterization of the Pharmacokinetic and Pharmacodynamic Profile of Apraglutide, a Glucagon-Like Peptide-2 Analog, in Healthy Volunteers. J Pharmacol Exp Ther. 2023; 386(2):129-137.
  • Meijer RPJ, Neijenhuis LKA, Zeilstra AP, et al. Data-Driven Identification of Targets for Fluorescence-Guided Surgery in Non-Small Cell Lung Cancer. Mol Imaging Biol. 2023; 25(1):228-239.
  • Ferreira GS, Dijkstra FM, Veening-Griffioen DH, et al. Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs. Transl Psychiatry. 2023; 13(1):74.
  • Stibbe JA, de Barros HA, Linders DGJ, et al. First-in-patient study of OTL78 for intraoperative fluorescence imaging of prostate-specific membrane antigen-positive prostate cancer: a single-arm, phase 2a, feasibility trial. Lancet Oncol. 2023; 24(5):457-467.
  • Stibbe JA, Hoogland P, Achterberg FB, et al. Highlighting the Undetectable - Fluorescence Molecular Imaging in Gastrointestinal Endoscopy. Mol Imaging Biol. 2023; 25(1):18-35.
  • Ten Voorde W, Akinseye C, Abdisalaam I, et al. Intradermal substance P as a challenge agent in healthy individuals. Clin Transl Sci. 2023; 16(10):1856-1865.
  • Zhuparris A, Maleki G, van Londen L, et al. A smartphone- and wearable-based biomarker for the estimation of unipolar depression severity. Sci Rep. 2023; 13(1):18844.
  • Smit V, de Mol J, Schaftenaar FH, et al. Single-cell profiling reveals age-associated immunity in atherosclerosis. Cardiovasc Res. 2023; 119(15):2508-2521.
  • Itano A, Maslin D, Ramani K, et al. Clinical translation of anti-inflammatory effects of Prevotella histicola in Th1, Th2, and Th17 inflammation. Front Med (Lausanne). 2023; 10:1070433.
  • Linders DGJ, Bijlstra OD, Fallert LC, et al. Cysteine Cathepsins in Breast Cancer: Promising Targets for Fluorescence-Guided Surgery. Mol Imaging Biol. 2023; 25(1):58-73.
  • ZhuParris A, de Goede AA, Yocarini IE, et al. Machine Learning Techniques for Developing Remotely Monitored Central Nervous System Biomarkers Using Wearable Sensors: A Narrative Literature Review. Sensors (Basel). 2023; 23(11):5243.
  • Bakkum MJ, Verdonk P, Thomas EG, et al; EurOP2E consortium. A Clinical Pharmacology and Therapeutics Teacher's Guide to Race-Based Medicine, Inclusivity, and Diversity. Clin Pharmacol Ther. 2023; 113(3):600-606.
  • Azari F, Meijer RPJ, Kennedy GT, et al. Carcinoembryonic Antigen-Related Cell Adhesion Molecule Type 5 Receptor-Targeted Fluorescent Intraoperative Molecular Imaging Tracer for Lung Cancer: A Nonrandomized Controlled Trial. JAMA Netw Open. 2023; 6(1):e2252885.
  • Assil S, Buters TP, Hameeteman PW, et al. Oral prednisolone suppresses skin inflammation in a healthy volunteer imiquimod challenge model. Front Immunol. 2023; 14:1197650.
  • Huisman BW, Nené LEH, Linders FLL, et al. No effect of topical digoxin and furosemide for patients with actinic keratosis. J Eur Acad Dermatol Venereol. 2023; 37(2):e172-e174.
  • Rousel J, Bergmans ME, van der Meulen LWJ, et al; NGID consortium. Guselkumab induction therapy demonstrates long-lasting efficacy in patients with mild psoriasis, results from a randomized, placebo-controlled exploratory clinical trial. J Am Acad Dermatol. Published online 2023.
  • van Huizen AM, van der Kraaij GE, Busard CI, et al. Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three-year follow-up data of a single-blind randomized controlled trial. J Eur Acad Dermatol Venereol. 2023; 37(9):1815-1824.
  • Kolkhir P, Laires PA, Salameh P, et al. The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria-CURE Results. J Allergy Clin Immunol Pract. 2023; 11(2):610-620.e5.
  • Vrouwe JPM, Hennus PML, Hamdy NAT, Osanto S, Willemse PM. Risk of osteoporosis in testicular germ cell tumour survivors: A systematic review of the literature. BJUI Compass. Published online 2023.
  • Recourt K, de Boer P, van der Ark P, et al. Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder. Transl Psychiatry. 2023; 13(1):266. doi: 10.1038/s41398-023-02557-5.
  • White NA, Oude Vrielink TJC, van der Bogt KEA, et al. Question-based development of high-risk medical devices: A proposal for a structured design and review process. Br J Clin Pharmacol. 2023; 89(7):2144-2159.
  • de Laat W, Pagan L, Malcolm RK, et al. First-in-human study to assess the pharmacokinetics, tolerability, and safety of single-dose oxybutynin hydrochloride administered via a microprocessor-controlled intravaginal ring. Drug Deliv. 2023; 30(1):2180113.
  • Goesmann L, Refaian N, Bosch JJ, Heindl LM. Characterization and Quantitation of the Tumor Microenvironment of Uveal Melanoma. Biology (Basel). 2023; 12(5):738.
  • Galema HA, Faber RA, Tange FP, et al; Upper-GI ICG quantification study group. A quantitative assessment of perfusion of the gastric conduit after oesophagectomy using near-infrared fluorescence with indocyanine green. Eur J Surg Oncol. 2023; 49(5):990-995.
  • Nădăban A, Rousel J, El Yachioui D, et al. Effect of sphingosine and phytosphingosine ceramide ratio on lipid arrangement and barrier function in skin lipid models. J Lipid Res. 2023; 64(8):100400. doi: 10.1016/j.jlr.2023.100400.
  • Kocatürk E, Salameh P, Sarac E, et al. Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU study. J Allergy Clin Immunol. 2023;152(5):1095-1106.
  • Zhuparris A, Maleki G, Koopmans I, et al. Smartphone and Wearable Sensors for the Estimation of Facioscapulohumeral Muscular Dystrophy Disease Severity: Cross-sectional Study. JMIR Form Res. 2023; 7:e41178.
  • Rousel J, Saghari M, Pagan L, et al. Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial. Int J Mol Sci. 2023; 24(18):14315.
  • Vissers MFJM, Troyer MD, Thijssen E, et al. A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls. Clin Transl Sci. 2023; 16(8):1408-1420.
  • Böttcher M, Düngen HD, Corcea V, et al. Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes. Am J Cardiovasc Drugs. 2023; 23(2):145-155.
  • Thiboutot DM, Craft N, Rissmann R, et al. Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne. J Dermatolog Treat. 2023 Dec;34(1):2138691.
  • Kools J, Aerts W, Niks EH, et al. Assessment of the burden of outpatient clinic and MRI-guided needle muscle biopsies as reported by patients with facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 2023; 33(5):440-446.
  • van Kraaij SJW, Gal P, Borghans LGJM, et al. First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator. Clin Transl Sci. 2023; 16(8):1381-1395.
  • ZhuParris A, Thijssen E, Elzinga WO, et al. Treatment Detection and Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part III Estimation Using Finger Tapping Tasks. Mov Disord. 2023; 38(10):1795-1805.
  • van Kraaij SJW, Pereira DR, Smal B, et al. Identification of peripheral vascular function measures and circulating biomarkers of mitochondrial function in patients with mitochondrial disease. Clin Transl Sci. 2023; 16(7):1258-1271.
  • Ten Voorde W, Saghari M, Boltjes J, et al. A multimodal, comprehensive characterization of a cutaneous wound model in healthy volunteers. Exp Dermatol. 2023; 32(7):1028-1041.
  • Prins S, Borghans L, de Kam ML, et al. Cognitive performance in healthy clinical trial participants and patients with the NeuroCart, a neurodegenerative disease measured with an automated neuropsychological and neurophysiological test battery. J Neurol Sci. 2023; 449:120658.
  • Brooks S, Zuiker R, Bleys C, et al. Pharmacological characterization of the selective orexin-1 receptor antagonist JNJ-61393215 in healthy volunteers. J Psychopharmacol. 2023; 37(6):577-589.
  • Baart VM, van Manen L, Bhairosingh SS, et al. Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors. Mol Imaging Biol. 2023; 25(1):122-132.
  • Hijma H, Koopmans I, Klaassen E, et al. A crossover study evaluating the sex-dependent and sensitizing effects of sleep deprivation using a nociceptive test battery in healthy subjects. Br J Clin Pharmacol. 2023; 89(1):361-371.
  • Debets MPM, Tummers FHMP, Silkens MEWM, et al. Doctors' alertness, contentedness and calmness before and after night shifts: a latent profile analysis. Hum Resour Health. 2023; 21(1):68.
  • Pagan L, Huisman BW, van der Wurff M, et al. The vulvar microbiome in lichen sclerosus and high-grade intraepithelial lesions. Front Microbiol. 2023; 14:1264768.
  • Prins MLM, van der Plas JL, Vissers MFJM, et al. Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: A phase 2a, open-label, single-dose escalation study. Br J Clin Pharmacol. 2023; 89(3):1105-1114.
  • In 't Veld AE, Grievink HW, van der Plas JL, et al. Immunosuppression by hydroxychloroquine: mechanistic proof in in vitro experiments but limited systemic activity in a randomized placebo-controlled clinical pharmacology study. Immunol Res. 2023; 71(4):617-627.
  • Post TE, Heijn LG, Jordan J, van Gerven JMA. Sensitivity of cognitive function tests to acute hypoxia in healthy subjects: a systematic literature review. Front Physiol. 2023; 14:1244279.
  • Koopmans I, Doll RJ, van der Wall H, et al. Fit for purpose of on-the-road driving and simulated driving: A randomised crossover study using the effect of sleep deprivation. PLoS One. 2023; 18(2):e0278300.
  • Heck J, Höner Zu Siederdissen C, Krause O, et al. Concordance of emergency department physicians' decisions on HIV post-exposure prophylaxis with national guidelines: results from a retrospective cohort study. Int Health. Published online 2023.
  • van Diemen MPJ, Ziagkos D, Kruizinga MD, et al. Mitochondrial function, grip strength, and activity are related to recovery of mobility after a total knee arthroplasty. Clin Transl Sci. 2023; 16(2):224-235.
  • In 't Veld AE, Jansen MAA, de Kam ML, et al. Immune Monitoring of Mycophenolate Mofetil Activity in Healthy Volunteers Using Ex Vivo T Cell Function Assays. Pharmaceutics. 2023; 15(6):1635.
  • Gosselt HR, van Lint JA, Kosse LJ, et al. Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseases. Expert Opin Drug Saf. 2023; 22(6):501-507.
  • van Minderhout HM, Joosse MV, Klaassen ES, Schalij-Delfos NE. EEG changes as an indication of central nervous system involvement following cyclopentolate 1% eye drops; a randomized placebo-controlled pilot study in a pediatric population. Strabismus. 2023; 31(2):82-96.
  • Houvast RD, Badr N, March T, et al. Preclinical evaluation of EpCAM-binding designed ankyrin repeat proteins (DARPins) as targeting moieties for bimodal near-infrared fluorescence and photoacoustic imaging of cancer. Eur J Nucl Med Mol Imaging. Published online 2023.
  • van Kraaij SJW, Borghans L, Klaassen ES, et al. Randomized placebo-controlled crossover study to assess tolerability and pharmacodynamics of zagociguat, a soluble guanylyl cyclase stimulator, in healthy elderly. Br J Clin Pharmacol. 2023; 89(12):3606-3617.
  • van der Plas JL, Kuiper VP, Bagchus WM, et al. Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands. Lancet Infect Dis. 2023; 23(10):1164-1174.
  • van Kraaij SJW, Hamblin MR, Pickering G, et al. A Phase 1 randomized, open-label clinical trial to evaluate the effect of a far-infrared emitting patch on local skin perfusion, microcirculation and oxygenation. Exp Dermatol. Published online 2023.
  • Nieuwkamer BB, Vrouwe JPM, Willemse PM, et al. Quantitative ultrasound of the calcaneus (QUS): A valuable tool in the identification of patients with non-metastatic prostate cancer requiring screening for osteoporosis. Bone Rep. 2023; 18:101679.
  • Otto ME, Bergmann KR, de Kam ML, et al. Item response theory in early phase clinical trials: Utilization of a reference model to analyze the Montgomery-Åsberg Depression Rating Scale. CPT Pharmacometrics Syst Pharmacol. 2023;12(10):1425-1436.
  • Donker EM, Pandit R, Poleij MCS, et al; Pharmacotherapy Education working group of the Dutch Society for Clinical Pharmacology & Biopharmacy and its affiliated Dutch Network of Clinical Pharmacology Teachers. The Dutch list of essential drugs for undergraduate medical education: A modified Delphi study. Br J Clin Pharmacol. 2023; 89(4):1431-1451.
  • Yfanti C, Vestbjerg B, Van't Westende J, et al. A phase 1 trial of AP30663, a KCa 2 channel inhibitor in development for conversion of atrial fibrillation. Br J Clin Pharmacol. Published online 2023.
  • Huisman BW, Pagan L, Ulrich M, et al. Reflectance confocal microscopy as a non-invasive imaging tool in vulvar high-grade squamous intraepithelial lesions and lichen sclerosus: A descriptive morphological study in patients and healthy volunteers. Exp Dermatol. 2023; 32(10):1734-1743.
  • Tong TML, Bastiaannet E, Speetjens FM, et al. Time Trends in the Treatment and Survival of 5036 Uveal Melanoma Patients in The Netherlands over a 30-Year Period. Cancers (Basel). 2023; 15(22):5419.
  • Wildenbeest FWH, Hassing GJ, Kemme MJB, et al. Heart rate stability in a clinical setting and after a short exercise in healthy male volunteers. Clin Physiol Funct Imaging. Published online 2023.
  • van Huizen A, Bank P, van der Kraaij G, et al. Quantifying the Effect of Methotrexate on Adalimumab Response in Psoriasis by Pharmacokinetic-Pharmacodynamic Modeling. J Invest Dermatol. 2023; S0022-202X(23)03103-2.
  • Wind SS, Jansen MAA, Rijsbergen M, et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers 2022, 14, 1510. Cancers (Basel). 2023; 15(5):1485.
  • Dijkstra FM, Zuiker RGJA, Heuberger JAAC, et al. Administration of oxathridine, a first-in-class histamine-3 receptor partial agonist in healthy male volunteers: Central nervous system depression and pseudo-hallucinations. Br J Clin Pharmacol. Published online 2023.
  • Bekkers VZ, Khan F, Aarts P, et al. Needle-free electronically-controlled jet injector treatment with bleomycin and lidocaine is effective and well-tolerated in patients with recalcitrant keloids. Lasers Surg Med. Published online 2023.
  • Donker EM, Osmani H, Brinkman DJ, et al; Education committee of the Dutch Society for Clinical Pharmacology and Biopharmacy. The impact of a summative national prescribing assessment and curriculum type on the development of the prescribing competence of junior doctors. Eur J Clin Pharmacol. 2023; 79(12):1613-1621.
  • Huisman BW, Pagan L, Naafs RGC, et al. Dermatoscopy and Optical Coherence Tomography in Vulvar High-Grade Squamous Intraepithelial Lesions and Lichen Sclerosus: A Prospective Observational Trial. J Low Genit Tract Dis. 2023; 27(3):255-261.
  • Giang J, van Doorn MBA, Diercks GFH, et al. Successful pharmacological intervention at different levels of the complement system in an in vitro complement fixation model for bullous pemphigoid. Exp Dermatol. 2023; 32(5):632-640.
  • Post TE, Schmitz J, Denney C, et al. Oral fructose intake does not improve exercise, visual, or cognitive performance during acute normobaric hypoxia in healthy humans. Front Nutr. 2023; 10:1170873.
  • Rousel J, Nădăban A, Saghari M, et al. Lesional skin of seborrheic dermatitis patients is characterized by skin barrier dysfunction and correlating alterations in the stratum corneum ceramide composition. Exp Dermatol. Published online 2023.
  • de Boer M, Gosselt HR, Jansen J, et al. Analysis and visualization of the course and burden over time of adverse drug reactions (ADRs) attributed to TNFα-inhibitors in patients with inflammatory rheumatic diseases (IRDs). Expert Opin Drug Saf. 2023; 22(3):195-202.

Interested in learning more?

Back to homepage